Iterum Therapeutics plc (ITRMF) Long-Term Deferred Tax (2017 - 2022)

Iterum Therapeutics' Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $36.1 million for Q4 2022.

• In Q4 2022, Long-Term Deferred Tax rose 8.55% year-over-year to $36.1 million; the TTM figure through Dec 2022 stood at $36.1 million (up 8.55% YoY), while the FY2022 annual figure was $36.1 million, up 8.55% from the prior year.
• Long-Term Deferred Tax for Q4 2022 stood at $36.1 million, up from $33.2 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $36.1 million in Q4 2022, with the low at $13.6 million in Q4 2018.
• The 5-year median for Long-Term Deferred Tax is $30.3 million (2020), against an average of $27.9 million.
• The sharpest annual moves came in 2018 and 2022: Long-Term Deferred Tax jumped 152.32% in 2018, then gained 8.55% in 2022.
• Iterum Therapeutics' Long-Term Deferred Tax stood at $13.6 million in 2018, then surged by 91.93% to $26.2 million in 2019, then advanced by 15.52% to $30.3 million in 2020, then rose by 9.77% to $33.2 million in 2021, then grew by 8.55% to $36.1 million in 2022.
• Business Quant data shows ITRMF's Long-Term Deferred Tax at $36.1 million in Q4 2022, $33.2 million in Q4 2021, and $30.3 million in Q4 2020.